REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN
Alpesh Amin(University of California, Irvine), Jeffrey Trocio(Pfizer (United States)), Jack Mardekian(Pfizer (United States)), Kevin Odell(Pfizer (United States)), Onur Başer(STATinMED (United States)), Chad Patel, Mario Mendoza(Pfizer (United States)), Shalabh Singhal(Integrated BioTherapeutics (United States)), Allison Keshishian(STATinMED (United States)), Lien Vo(Bristol-Myers Squibb (United States)), Kwanza Price(Pfizer (United States)), Lin Xie(Foshan University)
Cited by 2
Related Papers
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|93
Deep RNA sequencing reveals the dynamic regulation of miRNA, lncRNAs, and mRNAs in osteosarcoma tumorigenesis and pulmonary metastasis
|Cell Death and Disease|2018|88
miR‐200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to <scp>BRAF</scp> inhibitor treatment
|Pigment Cell & Melanoma Research|2015|53